title: Dose intensity analysis of melphalan and prednisone in multiple myeloma.
abstract: The average relative dose intensity (DI) of conventional oral melphalan and prednisone therapy received by 93 newly diagnosed multiple myeloma patients was correlated with survival and with percent reduction in M-protein. A survival advantage was shown with increasing average relative DI of melphalan and prednisone. Multivariate analysis showed survival to correlate with increasing DI of prednisone (P = .05) but not with the DI of melphalan (P = .93) nor with the percent decrement in M-protein (P = .10). These results suggest that the initial management of myeloma should be reassessed, with particular emphasis on more intensive therapy employing high-dose steroids.
authors: Cancer Research Group (McEachern Laboratory), University of Alberta, Edmonton, Canada.
authors: M
authors: M
authors: Palmer
authors: A
authors: A
authors: Belch
authors: J
authors: J
authors: Hanson
authors: L
authors: L
authors: Brox
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001798:Blood Proteins / Q000032:analysis; D006801:Humans; D007136:Immunoglobulins; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D011241:Prednisone / Q000008:administration & dosage
chemical_list: D001798:Blood Proteins; D007136:Immunoglobulins; C009823:M-proteins (Myeloma); D008558:Melphalan; D011241:Prednisone